Keyword: Protagonist Therapeutics
The oral alpha-4-beta-7 integrin antagonist performed badly enough in the first 65 patients for a committee to rule it would be futile to continue.
Johnson & Johnson has landed rights to Protagonist Therapeutics’ preclinical Crohn’s disease asset PTG-200.
There may be a slightly wider crack in the biotech IPO window this summer as Protagonist Therapeutics announces a larger-than-expected offering.
A year after the small, early-stage Californian IBD biotech Protagonist Therapeutics managed to raise $40 million, the company is now seeking to go public with a $75 million offering.